Flavanones inhibit the clonogenicity of HCT116 cololectal cancer cells

International Journal of Molecular Medicine

Volumn 29, Issue 3, 2012, Pages 403-408

  Woo, Yoonkyung ^a   Shin, Soon Young ^a   Hyun, Jiye ^a   Lee, Sung Dae ^b   Lee, Young Han ^a   Lim, Yoongho ^a  

^a Konkuk University   (South Korea)

^b National Institute of Animal Science   (South Korea)

Author keywords

Clonogenicity; Colorectal cancer; Flavanone; HCT116 cell; Quantitatively SAR

Indexed keywords

2' HYDROXYFLAVANONE; 2',3' DIMETHOXYFLAVANONE; 2',3',5 TRIMETHOXYFLAVANONE; 2',3',7 TRIMETHOXYFLAVANONE; 2',4',6 TRIMETHOXYFLAVANONE; 3' HYDROXYFLAVANONE; 3',4' DIMETHOXYFLAVANONE; 3',4',6 TRIMETHOXYFLAVANONE; 3',6 DIMETHOXYFLAVANONE; 4 METHOXYFLAVANONE; 4' HYDROXY 5,7 DIMETHOXYFLAVANONE; 4' HYDROXYFLAVANONE; 4',5',7 TRIMETHOXYFLAVANONE; 5 METHOXYFLAVANONE; 5',7' DIMETHOXYFLAVANONE; 6 CHLORO 3',4' DIMETHOXYFLAVANONE; 6 METHOXYFLAVANONE; 6' HYDROXYFLAVANONE; 7 HYDROXY 5 METHOXYFLAVANONE; 7 METHOXYFLAVANONE; 7' HYDROXYFLAVANONE; ANTINEOPLASTIC AGENT; FLAVANONE DERIVATIVE; FUSTIN; NARINGENIN; PINOSTROBIN; SAKURANETIN; TAXIFOLIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELL CYCLE G1 PHASE; CELL STRAIN HCT116; CLONOGENESIS; COLORECTAL CANCER; CONTROLLED STUDY; DRUG STRUCTURE; HUMAN; HUMAN CELL; INHIBITION KINETICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS; CARBOHYDRATE CONFORMATION; COLORECTAL NEOPLASMS; FLAVANONES; HCT116 CELLS; HUMANS; MODELS, MOLECULAR; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR STEM CELL ASSAY;

EID: 84862932556     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2011.857     Document Type: Article

References (25)

1. Goldwasser J, Cohen PY, Lin W, Kitsberg D, Balaguer P, Polyak SJ, Chung RT, Yarmush ML and Nahmias Y: Naringenin inhibits the assembly and long-term production of infectious hepatitis C virus particles through a PPAR-mediated mechanism. J Hepatol 55: 963-971, 2011.
2. Xu YJ, Capistrano R I, Dhooghe L, Foubert K, Lemière F, Maregesi S, Baldé A, Apers S and Pieters L: Herbal medicines and infectious diseases: characterization by LC-SPE-NMR of some medicinal plant extracts used against malaria. Planta Med 77: 1139-1148, 2011.
3. Choi SE, Park KH, Han BH, Jeong MS, Seo SJ, Lee DI, Joo SS and Lee MW: Inhibition of inducible nitric oxide synthase and cyclooxygenase-2 expression by phenolic compounds from roots of Rhododendron mucronulatum. Phytother Res 25: 1301-1305, 2011.
4. Sheu MJ, Chou PY, Cheng HC, Wu CH, Huang GJ, Wang BS, Chen JS, Chien YC and Huang MH: Analgesic and anti-inflammatory activities of a water extract of Trachelospermum jasminoides (Apocynaceae). J Ethnopharmacol 126: 332-338, 2009.
5. Jin CH, Shin EJ, Park JB, Jang CG, Li Z, Kim MS, Koo KH, Yoon HJ, Park SJ, Choi WC, et al: Fustin flavonoid attenuates β-amyloid (1-42)-induced learning impairment. J Neurosci Res 87: 3658-3670, 2009.
6. Park BC, Lee YS, Park HJ, Kwak MK, Yoo BK, Kim JY and Kim JA: Protective effects of fustin, a flavonoid from Rhus verniciflua stokes, on 6-hydroxydopamine-induced neuronal cell death. Exp Mol Med 39: 316-326, 2007.
7. Park KY, Jung GO, Lee KT, Choi J, Choi MY, Kim GT, Jung HJ and Park HJ: Antimutagenic activity of flavonoids from the heartwood of Rhus verniciflua. J Ethnopharmacol 90: 73-79, 2004. (Pubitemid 38091689)
8. Shi LL, Chen BN, Gao M, Zhang HA, Li YJ, Wang L and Du GH: The characteristics of therapeutic effect of pinocembrin in transient global brain ischemia/reperfusion rats. Life Sci 88: 521-528, 2011.
9. Punvittayagul C, Wongpoomchai R, Taya S and Pompimon W: Effect of pinocembrin isolated from Boesenbergia pandurata on xenobiotic-metabolizing enzymes in rat liver. Drug Metab Lett 5: 1-5, 2011.
10. Diaz Napal GN, Defagó MT, Valladares GR and Palacios SM: Response of Epilachna paenulata to two flavonoids, pinocembrin and quercetin, in a comparative study. J Chem Ecol 36: 898-904, 2010.
11. Malek SN, Phang CW, Ibrahim H, Norhanom AW and Sim KS: Phytochemical and cytotoxic investigations of Alpinia mutica rhizomes. Molecules 16: 583-589, 2011.
12. Wan L, Sun X, Wang X, Li Y, Yu Q and Guo C: A stereospecific HPLC method and its application in determination of pharmacokinetics profile of two enantiomers of naringenin in rats. J Chromatogr Sci 49: 316-320, 2011.
13. Vega-Villa KR, Remsberg CM, Takemoto JK, Ohgami Y, Yáñez JA, Andrews PK and Davies NM: Stereospecific pharmacokinetics of racemic homoeriodictyol, isosakuranetin, and taxifolin in rats and their disposition in fruit. Chirality 23: 339-348, 2011.
14. Santos FC, Abreu P, Castro HC, Paixão IC, Cirne-Santos CC, Giongo V, Barbosa JE, Simonetti BR, Garrido V, Bou-Habib DC, et al: Synthesis, antiviral activity and molecular modeling of oxoquinoline derivatives. Bioorg Med Chem 17: 5476-5481, 2009.
15. Meyerhardt JA: Beyond standard adjuvant therapy for colon cancer: role of nonstandard interventions. Semin Oncol 38: 533-541, 2011.
16. de Gramont A, de Gramont A, Chibaudel B, Bachet JB, Larsen AK, Tournigand C, Louvet C and André T: GERCOR from chemotherapy to targeted therapy in adjuvant treatment for stage III colon cancer. Semin Oncol 38: 521-532, 2011.
17. Komatsu Y, Yuki S, Sogabe S, Fukushima H, Iwanaga I, Kudo M, Tateyama M, Meguro T, Uebayashi M, Saga A, Sakata Y and Asaka M: Phase II study of combined treatment with irinotecan and S-1 (IRIS) in patients with inoperable or recurrent advanced colorectal cancer (HGCSG0302). Oncology 80: 70-75, 2011.
18. Franken NA, Rodermond HM, Stap J, Haveman J and van Bree C: Clonogenic assay of cells in vitro. Nat Protoc 1: 2315-2319, 2006.
19. Waf1/Cip1 gene transcription via early growth response-1 (Egr-1) in C6 glioma cells. Exp Mol Med 42: 395-405, 2010.
20. Lee S, Woo Y, Shin SY, Lee YH and Lim Y: Relationships between the structures of flavanone derivatives and their effects in enhancing early growth response-1 gene expression. Bioorg Med Chem Lett 19: 2116-2120, 2009.
21. Jez JM, Bowman ME, Dixon RA and Noel JP: Structure and mechanism of the evolutionarily unique plant enzyme chalcone isomerase. Nat Struct Biol 7: 786-791, 2000.
22. Ross DD, Joneckis CC, Ordóñez JV, Sisk AM, Wu RK, Hamburger AW Nora RE and Nora RE: Estimation of cell survival by flow cytometric quantification of fluorescein diacetate/propidium iodide viable cell number. Cancer Res 49: 3776-3782, 1989.
23. Harper JW, Adami GR, Wei N, Keyomarsi K and Elledge SJ: The p21 cdk-interacting protein cipl is a potent inhibitor of Gl cyclin-dependent kinases. Cell 75: 805-816, 1993. (Pubitemid 23346377)
24. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, Sedivy JM, Kinzler KW and Vogelstein B: Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282: 1497-1501, 1998.
25. Hinds PW, Dowdy SF, Eaton EN, Arnold A and Weinberg RA: Function of a human cyclin gene as an oncogene. Proc Natl Acad Sci USA 91: 709-713, 1994. (Pubitemid 24041471)